Stroke risk after transcatheter aortic valve replacement in patients with carotid stenosis: A systematic review and meta-analysis.

Aortic valve stenosis Carotid artery stenosis Stroke Transcatheter aortic valve implantation Transcatheter aortic valve replacement

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 May 2024
Historique:
received: 07 01 2024
revised: 02 04 2024
accepted: 19 04 2024
medline: 4 5 2024
pubmed: 4 5 2024
entrez: 3 5 2024
Statut: aheadofprint

Résumé

Stroke is a feared complication of transcatheter aortic valve replacement (TAVR). Patients undergoing TAVR typically have multiple comorbidities, such as carotid artery stenosis (CAS). We conducted the present meta-analysis to determine the risk of stroke and mortality following TAVR in patients with CAS. We searched PubMed/Medline, Scopus, ScienceDirect, and Cochrane Clinical Trials databases for clinical studies that compared CAS ≥50% and CAS ≥70% versus non-CAS TAVR population. The endpoints included the 30-day incidence of stroke or transient ischemic attack (TIA) and 30-day all-cause of mortality. We identified seven studies that included 12,418 patients in the CAS group and 102,316 in the control group. CAS ≥50% was not associated with an increased risk of 30-day stroke or TIA after TAVR [risk ratio (RR): 1.38; 95% confidence interval (95% CI): 0.95-2.02; p = 0.09]. However, patients with CAS ≥70% had an increased risk of stroke or TIA (RR: 1.43; 95% CI: 1.02-2.01; p = 0.04). No difference in 30-day all-cause mortality was observed between CAS ≥50% or CAS ≥70% and control groups (RR: 1.09; 95% CI: 0.79-1.52; p = 0.59 and RR: 1.11; 95% CI: 0.85-1.45; p = 0.43, respectively). CAS ≥70% was associated with an increased risk of stroke or TIA following TAVR compared with patients without CAS.

Sections du résumé

BACKGROUND BACKGROUND
Stroke is a feared complication of transcatheter aortic valve replacement (TAVR). Patients undergoing TAVR typically have multiple comorbidities, such as carotid artery stenosis (CAS). We conducted the present meta-analysis to determine the risk of stroke and mortality following TAVR in patients with CAS.
METHODS METHODS
We searched PubMed/Medline, Scopus, ScienceDirect, and Cochrane Clinical Trials databases for clinical studies that compared CAS ≥50% and CAS ≥70% versus non-CAS TAVR population. The endpoints included the 30-day incidence of stroke or transient ischemic attack (TIA) and 30-day all-cause of mortality.
RESULTS RESULTS
We identified seven studies that included 12,418 patients in the CAS group and 102,316 in the control group. CAS ≥50% was not associated with an increased risk of 30-day stroke or TIA after TAVR [risk ratio (RR): 1.38; 95% confidence interval (95% CI): 0.95-2.02; p = 0.09]. However, patients with CAS ≥70% had an increased risk of stroke or TIA (RR: 1.43; 95% CI: 1.02-2.01; p = 0.04). No difference in 30-day all-cause mortality was observed between CAS ≥50% or CAS ≥70% and control groups (RR: 1.09; 95% CI: 0.79-1.52; p = 0.59 and RR: 1.11; 95% CI: 0.85-1.45; p = 0.43, respectively).
CONCLUSIONS CONCLUSIONS
CAS ≥70% was associated with an increased risk of stroke or TIA following TAVR compared with patients without CAS.

Identifiants

pubmed: 38702030
pii: S0167-5273(24)00707-1
doi: 10.1016/j.ijcard.2024.132085
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132085

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Fernando Garagoli (F)

Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Electronic address: fernando.garagoli@hospitalitaliano.org.ar.

Juan Guido Chiabrando (JG)

Department of Interventional Cardiology, Sanatorio Anchorena, Buenos Aires, Argentina.

Ignacio Miguel Seropian (IM)

Department of Interventional Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Marco Lombardi (M)

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Viale Benedetto XV, 6 - 16132, Genoa, Italy.

Carla Romina Agatiello (CR)

Department of Interventional Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

María Luz Fernández Recalde (MLF)

Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Rocco Vergallo (R)

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Viale Benedetto XV, 6 - 16132, Genoa, Italy; Cardiothoracic and Vascular Department (DICATOV), IRCCS San Martino Hospital, Viale Mali Benedetto XV, 6 - 16132, Genoa, Italy.

Italo Porto (I)

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Viale Benedetto XV, 6 - 16132, Genoa, Italy; Cardiothoracic and Vascular Department (DICATOV), IRCCS San Martino Hospital, Viale Mali Benedetto XV, 6 - 16132, Genoa, Italy.

Ignacio Martín Bluro (IM)

Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Classifications MeSH